PA
MDGL icon

Perceptive Advisors’s Madrigal Pharmaceuticals MDGL Stock Holding History

Perceptive Advisors’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46,500
Closed -$15.4M – 98
2025
Q1 		$15.4M Buy
+46,500
New +$15.3M 0.54% 41
2024
Q3 		– Sell
-264,600
Closed -$74.1M – 117
2024
Q2 		$74.1M Sell
264,600
-165,353
-38% -$39.4M 1.79% 13
2024
Q1 		$115M Buy
429,953
+278,802
+184% +$65.7M 2.01% 13
2023
Q4 		$35M Buy
151,151
+26,514
+21% +$4.64M 0.78% 40
2023
Q3 		$18.2M Sell
124,637
-178,350
-59% -$33.6M 0.61% 45
2023
Q2 		$70M Sell
302,987
-347,575
-53% -$94.1M 2.03% 15
2023
Q1 		$158M Sell
650,562
-81,370
-11% -$22.2M 4.65% 5
2022
Q4 		$212M Buy
731,932
+400,909
+121% +$39.2M 5.97% 3
2022
Q3 		$21.5M Sell
331,023
-36,478
-10% -$2.53M 0.62% 43
2022
Q2 		$26.3M Buy
367,501
+89,215
+32% +$6.56M 0.82% 29
2022
Q1 		$27.3M Buy
278,286
+191,886
+222% +$16.2M 0.55% 45
2021
Q4 		$7.32M Buy
+86,400
New +$7.1M 0.11% 105
2018
Q4 		– Sell
-2,213
Closed -$474K – 116
2018
Q3 		$474K Sell
2,213
-30,000
-93% -$7.53M 0.01% 105
2018
Q2 		$9.01M Sell
32,213
-110,309
-77% -$19.4M 0.24% 61
2018
Q1 		$16.6M Sell
142,522
-46,371
-25% -$5.72M 0.47% 50
2017
Q4 		$17.3M Buy
+188,893
New +$10.8M 0.57% 47
2013
Q4 		– Sell
-68,035
Closed -$15M – 125
2013
Q3 		$15M Sell
68,035
-8,915
-12% -$1.9M 1.22% 18
2013
Q2 		$13.4M Buy
+76,950
New +$20.1M 1.36% 16

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Perceptive Advisors's MDGL Position: Q2 2025 in Review

Perceptive Advisors sold out of Madrigal Pharmaceuticals (MDGL) in Q2 2025, closing a stake of 46,500 shares — an estimated $15.4M sold.

Perceptive Advisors first reported a position in MDGL in Q2 2013 and held it in 18 quarters. The position peaked at $212M in Q4 2022. 305 funds tracked by Wall St. Rank hold MDGL as of Q2 2025.

  • Perceptive Advisors reported no remaining Madrigal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Perceptive Advisors sold 46,500 Madrigal Pharmaceuticals shares in Q2 2025, an estimated $15.4M.
  • Perceptive Advisors first reported a position in Madrigal Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Perceptive Advisors's Madrigal Pharmaceuticals position peaked at $212M in Q4 2022.
  • 305 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2025.

Based on Perceptive Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.